Article
Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.
The Journal of biological chemistry - 28 Apr 2000
Marx P F, Hackeng T M, Dawson P E, Griffin J H, Meijers J C, Bouma B N
Abstract excerpt
Thrombin-activable fibrinolysis inhibitor (TAFI) is present in the circulation as an inactive zymogen. Thrombin converts TAFI to a carboxypeptidase B-like enzyme (TAFIa) by cleaving at Arg(92) in a process accelerated by the cofactor, thrombomodulin. TAFIa attenuates fibrinolysis. TAFIa can be inactivated by both proteolysis by thrombin and spontaneous temperature-dependent loss of activity. The identity of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
